pretreatment

Original Contribution

Safety of Percutaneous Coronary Intervention Without P2Y12 Inhibitor Pretreatment From a Cohort of Unselected Patients

07/15/2018

Pierre Robert , MD;

Patrick Messner-Pellenc , MD, PhD;

Florence Leclercq , MD, PhD;

Guillaume Cayla , MD, PhD;

Benoit Lattuca , MD;

David Belardi , MD;

Christophe Demattei , MD;

Laurent Schmutz , MD;

Luc Cornillet , MD;

Bertrand Ledermann , MD;

Jean-Christophe Macia , MD;

A. Lemmi , MD;

Richard Gervasoni , MD;

Francois Roubille , MD, PhD;

Thien Tri Cung , MD;

Recent studies have challenged systematic pretreatment with a P2Y12 inhibitor before PCI in elective and NSTEMI patients. This study assesses outcomes after performing PCI immediately after coronary angiography with an exclusive...

Recent studies have challenged...

07/15/2018

Journal of Invasive Cardiology

Original Contribution

Contemporary Trends and Outcomes Associated With the Preprocedural Use of Oral P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2)

04/15/2017

Milan Seth , BS, MS;

Hitinder S. Gurm , MBBS, MD, FSCAI;

Devraj Sukul , MD;

Akshay Khandelwal , MD;

Simon R. Dixon , MBChB, FACC, FRACP, MD;

Thomas A. LaLonde , MD;

We sought to describe trends in the use of preprocedural P2Y12 inhibitors and their clinical impact in patients undergoing percutaneous coronary intervention (PCI).

We sought to describe trends in...

04/15/2017

Journal of Invasive Cardiology